Order byBest matchMost fresh

Sarepta shares rebound

Digest more
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
By Bhanvi Satija and Siddhi Mahatole (Reuters) -Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the therapy's withdrawal from the market.

Continue reading

FDA allows Sarepta to resume some Elevidys shipments
PharmExec · 1h
Sarepta Stock On the Rise Following Resumption of Elevidys Shipments in US
Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments
Shares of Sarepta surged Tuesday, a day after the FDA said the company could lift a voluntary pause on shipments of its Elevidys drug, which had been linked to three patient deaths this year.

Continue reading

Sarepta Therapeutics to Lift Pause on Shipments of Duchenne Treatment Elevidys
Parents call on FDA for path forward after Duchenne's gene therapy pause | Morning in America
Sarepta's FDA woes raise questions for future of gene therapy treatments
While Sarepta’s challenges could push some away from investing in gene therapies, it could also lead to interest in different approaches.

Continue reading

FDA recommends lifting voluntary hold on Elevidys in ambulatory patients
STAT · 23h
FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt

Sarepta Soars After FDA Says Some Patients Can Get Elevidys

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.

Sarepta: SRPT Stock To $40?

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially double from current levels to around $40
pharmaphorum9h

FDA gives the go-ahead to restart Elevidys shipments

In a statement, the Cambridge, Massachusetts-based company said that shipments of Elevidys (delandistrogene moxeparvovec) will restart while it continues dialogue with the FDA "on next steps in the safety labelling process and risk-mitigation approach for non-ambulatory patients."
BioSpace4d

Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an anonymous senior FDA official. Given Elevidys’ full approval, however, experts told BioSpace this path would set up a length legal battle between the regulator and
Feedback